Global Alpha Lipoic Acid Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Alpha Lipoic Acid Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Lipoic acid (LA), also known as α-lipoic acid, alpha-lipoic acid (ALA) and thioctic acid, is an organosulfur compound derived from caprylic acid (octanoic acid). ALA is made in animals normally and is essential for aerobic metabolism. It is also manufactured and is available as a dietary supplement in some countries where it is marketed as an antioxidant and is available as a pharmaceutical drug in other countries.

Market Overview:

The latest research study on the global Alpha Lipoic Acid market finds that the global Alpha Lipoic Acid market reached a value of USD 112.06 million in 2022. It’s expected that the market will achieve USD 181.65 million by 2028, exhibiting a CAGR of 8.38% during the forecast period.

COVID-19 affects the market for alpha lipoic acid.

The outbreak of COVID-19 first caused residents' concerns and government restrictions. The paralysis of traffic around the world, the sharp drop in trade and the shutdown or closure of factories have severely affected the global market. The economic downturn has led to a decline in the purchasing power of residents, while travel restrictions have reduced residents' travel. This has affected the market demand and production of alpha lipoic acid. However, the outbreak of COVID-19 has led to an increase in the health and hygiene awareness of global residents, and governments and companies have increased their R&D investment in the medical industry. As a therapeutic drug for liver diseases, many companies, academic institutions, and R&D institutions have invested in lipoic acid for COVID-19 research. For example, researchers at the University of Catania in Italy investigated whether natural compounds can prevent disease progression. Their research published in the Journal of Clinical Medicine found that iron chelators and protease inhibitors can resist SARS-CoV-2 infection. And alpha lipoic acid is one of their researches. These factors have conversely promoted the development of the alpha lipoic acid industry.

COVID-19 affects the industrial chain.

In the current market economy, the upstream and downstream industrial chains have never been so closely linked. The COVID-19 pandemic has caused a large number of factories to stop production, isolate employees from work, and obstruct transportation. The production of alpha lipoic acid industry has also been affected by COVID-19. If the supply of raw materials is blocked, the production of alpha lipoic acid will also be restricted. At the same time, the sales of alpha lipoic acid and the production and sales of downstream products will also be affected in many ways. Reduced demand in the downstream market will result in a reduction in the demand for alpha lipoic acid. Therefore, dealing with the impact of COVID-19 on the supply chain is also one of the important issues that alpha lipoic acid manufacturers need to deal with.

In the fields of materials and cosmetics.

At present, lipoic acid is widely used in the treatment of liver disease, diabetes, AIDS, psoriasis, eczema, Parkinson's disease, rheumatism, heart disease and other diseases. In recent years, there have been more and more reports on the application of lipoic acid in the treatment of diseases, especially in the field of refractory diseases, and lipoic acid has become the focus of medical research. At present, the application of lipoic acid is mainly concentrated in the medical field. For other applications such as materials, cosmetics and other fields have just begun, the application fields of lipoic acid need to be further expanded. In these areas that are still under research, alpha lipoic acid has great potential and opportunities.

Alpha lipoic acid is used as a side effect of the drug.

Alpha lipoic acid can affect insulin metabolism and lower blood sugar. Possible minor side effects and adverse reactions that have been reported include: skin allergic reactions, including rash, urticaria and itching, abdominal pain, nausea, vomiting, diarrhea, dizziness, urine malodor, etc., especially when used in large doses. These side effects make the choices of patients and doctors more cautious. This is a risk that affects the development of the market, and this type of risk has less impact.

The growth of health foods and dietary supplements.

Lipoic acid is a vitamin B compound that has both fat-soluble and water-soluble properties. It can exert its antioxidant effect through various mechanisms such as scavenging free radicals and regenerating other antioxidants. The antioxidant capacity is 400 times that of vitamin C and vitamin E. Alpha lipoic acid currently has a wide range of applications in the medical industry, and is also used in the production of many health foods and dietary supplements. The growth of the health food and dietary supplement industries over the years has promoted the development of the alpha lipoic acid industry.

Region Overview:

In global comparison, a significant portion of the revenue was generated in Asia Pacific (54.25% in 2021).

Company Overview:

Tonghe is one of the major players operating in the Alpha Lipoic Acid market, holding a share of 55.2% in 2022.

Tonghe

Jiangsu Tohope Pharmaceutical Co, Ltd (Tohope Pharma), which the precursor is Changshu Wanxing Chemical Co, Ltd, is a State high-tech enterprise engaging in research, development, production and sales of the formulations, Apls and health food products. The company has GMP certificates for raw materials, tablets, capsules and granules. The main products are Alpha Lipoic Acid, 6,8-Dichloro Ethyl Caprylate, R (+)-Alpha Lipoic Acid Sodium Salt, Metformin hydrochloride. Thioctic Acid Tablets and capsules, and TangPingPian which is the healthy food that regulates blood sugar and control complications.

Fushilai Pharmaceutical

Suzhou Fushilai Pharmaceutical Co., Ltd. (Fushilai Pharmaceutical) was formerly known as Changshu Fushilai Medicine&Chemical Co., Ltd. The company mainly focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, Phosphatidylcholine, three series of products, which belong to high-tech bio-pharmaceutical products encouraged by the country. Their products are mainly used in medicine, dietary supplement, cosmetics and other fields with the functions of oxidation resistance, delaying ageing, improving blood glucose, etc.

Segmentation Overview:

By type, Medical Level segment accounted for the largest share of market in 2021.

Application Overview:

The market's largest segment by application is the segment Diabetes Treatment, with a market share of 45.39% in 2021.

Chronic Hepatitis Treatment

Chronic hepatitis is inflammation of the liver that lasts at least 6 months. Common causes include hepatitis B and C viruses and certain drugs. Most people have no symptoms, but some have vague symptoms, such as a general feeling of illness, poor appetite, and fatigue. Alpha lipoic acid can be used for the treatment of chronic hepatitis and improve liver function.

Cirrhosis Treatment

Cirrhosis is an advanced stage of liver scarring (fibrosis), caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. Every time a person's liver is injured—whether due to disease, excessive drinking, or other reasons—it tries to repair itself. The patient may feel fatigue, weakness, and weight loss at first. In the later stages, patients may experience jaundice (yellowing of the skin), gastrointestinal bleeding, abdominal swelling, and confusion. Lipoic acid can be used in the treatment of liver cirrhosis.

Diabetes Treatment

Diabetes is a disease in which the body's blood sugar or blood sugar levels are too high. Diabetes is a chronic disease. Diabetes occurs when the pancreas cannot produce enough insulin or the body cannot effectively use the produced insulin. Insulin is a hormone that regulates blood sugar. High blood sugar or elevated blood sugar is a common consequence of uncontrolled diabetes, which can cause serious damage to many human systems, especially nerves and blood vessels, over time. Lipoic acid can significantly reduce insulin and improve insulin sensitivity (HOMA-IR), and lipoic acid can improve insulin resistance. So lipoic acid can be used to improve diabetes.

Fatty Liver Treatment

Fatty liver, also known as hepatic lipidosis or hepatic obesity, is a reversible condition. Refers to the pathological changes of excessive fat accumulation in liver cells caused by various reasons. It is a common pathological change of the liver, rather than an independent disease. Fatty liver disease is a serious threat to human health, becoming the second largest liver disease after viral hepatitis, with an increasing incidence and a younger age of onset. Normal human liver tissue contains a small amount of fat, such as triglycerides, phospholipids, glycolipids and cholesterol, whose weight is about 3% to 5% of liver weight. If the accumulation of fat in the liver is too much, more than 5% of the weight of the liver, or more than 50% of the liver cells have fatty degeneration in histology, it can be called fatty liver. The clinical manifestations are asymptomatic in mild cases, and fierce in severe cases. Generally speaking, fatty liver is a reversible disease, and early diagnosis and timely treatment can often return to normal. Alpha lipoic acid can also be used in the treatment of fatty liver.

Key Companies in the global Alpha Lipoic Acid market covered in Chapter 3:

Olon SpA (Infa Group)
Shyndec
Fushilai Pharmaceutical
Shandong Luning Pharmaceutical Co., Ltd.
Maidesen
Tonghe
Wuhan Honor Bio-Pharm Co., Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the Alpha Lipoic Acid market from 2018 to 2029 is primarily split into:

Experimental Level
Medical Level

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Alpha Lipoic Acid market from 2018 to 2029 covers:

Chronic Hepatitis Treatment
Cirrhosis Treatment
Diabetes Treatment
Fatty Liver Treatment
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)